

**S2 Table.** Risk factors for severe to critical COVID-19 in patients with B-cell lymphoma treated with B-cell depleting agents

	Severe to critical (n=27)	Non-severe (n=27)	Univariate		Multivariable	
			OR (95% CI)	p-value	aOR (95% CI)	p-value
Age (per 1-year increase)	74 (63-76)	62 (54-69)	1.08 (1.02-1.14)	0.008	1.06 (1.00-1.13)	0.035
Male sex	18 (66.7)	16 (59.3)	1.38 (0.45-4.17)	0.574		
BMI	21.9 (19.2-24.7)	24.0 (22.0-26.9)	0.86 (0.74-1.01)	0.067		
Vaccination status						
Fully vaccinated	20 (74.1)	22 (81.5)	0.65 (0.18-2.38)	0.514		
Underlying comorbidities						
HTN	11 (40.7)	7 (25.9)	1.96 (0.62-6.22)	0.251		
DM	6 (22.2)	6 (22.2)	1.00 (0.28-3.61)	> 0.999		
CKD	1 (3.7)	1 (3.7)	1.00 (0.06-16.85)	> 0.999		
CVD	0	1 (3.7)	-	> 0.999		
Chronic lung disease	2 (7.4)	2 (7.4)	1.00 (0.13-7.67)	> 0.999		
ECOG performance status						
0-1	24 (88.9)	25 (92.6)	1.00			
≥ 2	3 (11.1)	2 (7.4)	1.56 (0.24-10.19)	0.641		
B-cell depleting therapy						
RTX	15 (55.6)	25 (92.6)	1.00		1.00	
TCE	12 (44.4)	2 (7.4)	10.00 (1.96-50.94)	0.006	7.08 (1.29-38.76)	0.024
Total duration of TCE or RTX therapy	267 (130-393)	119 (78-148)	1.00 (1.00-1.00)	0.336		
Interval > 1 year from last TCE or RTX to COVID-19 diagnosis	3 (11.1)	7 (25.9)	0.44 (0.10-1.97)	0.282		
Prior lymphoma therapy						
Autologous stem-cell transplant	2 (7.4)	6 (22.2)	0.36 (0.08-1.56)	0.172		
CAR T-cell therapy	0	1 (3.7)	-	> 0.999		
Bendamustine therapy	13 (61.9)	8 (29.6)	2.21 (0.72-6.75)	0.166		
Lymphoma status						
Response <sup>a)</sup>	20 (80.0)	17 (73.9)	1.00			
Non-response	5 (20.0)	6 (26.1)	0.71 (0.18-2.74)	0.617		
Dominant variant						
Omicron	26 (96.3)	23 (85.2)	1.00			
Delta	1 (3.7)	4 (14.8)	0.22 (0.02-2.12)	0.191		

Values are presented as median (IQR) or number (%). aOR, adjusted odds ratio; BMI, body mass index; CAR, chimeric antigen receptor; CI, confidence interval; CKD, chronic kidney disease; COVID-19, coronavirus disease 2019; CVD, cardiovascular disease; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; HTN, hypertension; IQR, interquartile range; OR, odds ratio; RTX, rituximab; TCE, T-cell engager. <sup>a)</sup>Include complete or partial response to treatment.